| pubmed-article:10561261 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10561261 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10561261 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:10561261 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:10561261 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:10561261 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:10561261 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:10561261 | pubmed:dateCreated | 2000-6-7 | lld:pubmed |
| pubmed-article:10561261 | pubmed:abstractText | To investigate the activity and toxicity of gemcitabine as a single agent in patients with advanced non-small-cell lung cancer (NSCLC) after recurrence or failure of previous treatment with a platinum-containing regimen. | lld:pubmed |
| pubmed-article:10561261 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10561261 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10561261 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10561261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10561261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10561261 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10561261 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10561261 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10561261 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:RossiAA | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:TonatoMM | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:RinaldiMM | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:De MarinisFF | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:ScagliottiGG | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:GridelliCC | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:SelvaggiGG | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:CrinòLL | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:CalandriCC | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:MosconiA MAM | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:NovelloSS | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:Della... | lld:pubmed |
| pubmed-article:10561261 | pubmed:author | pubmed-author:NosedaMM | lld:pubmed |
| pubmed-article:10561261 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10561261 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:10561261 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10561261 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10561261 | pubmed:pagination | 2081-5 | lld:pubmed |
| pubmed-article:10561261 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:meshHeading | pubmed-meshheading:10561261... | lld:pubmed |
| pubmed-article:10561261 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10561261 | pubmed:articleTitle | Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. | lld:pubmed |
| pubmed-article:10561261 | pubmed:affiliation | Medical Oncology Division, Policlinico Hospital, Perugia, Italy. oncmedpg@krenet.it | lld:pubmed |
| pubmed-article:10561261 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10561261 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10561261 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10561261 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10561261 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10561261 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10561261 | lld:pubmed |
